Hms Capital Management, LLC Incyte Corp Transaction History

Hms Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 Apr 12, 2021	SELL	$76.02 - $100.5 $319,131 - $421,899	-4,198 Closed	0 $0
Q4 2020 Jan 29, 2021	SELL	$80.74 - $97.7 $28,581 - $34,585	-354 Reduced 7.78%	4,198 $365,000
Q3 2020 Oct 20, 2020	SELL	$85.07 - $109.69 $100,807 - $129,982	-1,185 Reduced 20.66%	4,552 $408,000
Q2 2020 Jul 31, 2020	BUY	$74.18 - $108.93 $425,570 - $624,931	5,737 New	5,737 $596,000
Q1 2020 Apr 27, 2020	SELL	$63.18 - $85.97 $1.28 Million - $1.74 Million	-20,289 Closed	0 $0
Q4 2019 Jan 29, 2020	SELL	$73.04 - $95.72 $13,001 - $17,038	-178 Reduced 0.87%	20,289 $1.77 Million
Q3 2019 Oct 15, 2019	SELL	$72.82 - $86.52 $30,948 - $36,771	-425 Reduced 2.03%	20,467 $0
Q2 2019 Jul 12, 2019	BUY	$73.52 - $88.7 $1.54 Million - $1.85 Million	20,892 New	20,892 $1.78 Million

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Hms Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Hms Capital Management, LLC with notifications on news.